Łukasiewicz – Polish Center for Technology Development

Łukasiewicz – PORT (https://port.lukasiewicz.gov.pl/en/) is part of the Łukasiewicz Research Network, the third-largest research network in Europe, connecting over 26 institutes from all over Poland. The research activity of Łukasiewicz – PORT is based on three centers: Materials Science, Life Sciences & Biotechnology, and Population Diagnostics. Research Groups as well as specialized and measurement laboratories operate within these units. Each center can focus on selected scientific and technological issues and comprehensively carry out research work and pilot research for industry. 

The Life Sciences & Biotechnology Center is a modern institution with a research, development, and implementation profile. It focuses on significant non-communicable diseases (NCDs) and develops competencies in neurobiology, oncology, biotechnology and biobanking. Its research teams deal with important research topics and collaborate with other research institutes, as well as provide services to external clients. Within the Center, the Biobank Research Group Biobank – PORT (lukasiewicz.gov.pl) is one of the few groups in Poland with a Biobank Unit within its structure and is the National Leading Centre for biobanking. It also acts as a national node in the European Network of Biobanking and Molecular Resources Research Infrastructure (BBMRI-ERIC) in EU Countries. 

The Center for Population Diagnostics is the first of its kind in Poland. It aims to conduct research in the field of modern diagnostic methods for many infectious diseases (e.g. AH1N1, SARS) and NCDs (e.g. cardiovascular diseases, cancer, diabetes, and obesity). The Center for Population Diagnostics significantly contributes to increasing the biomedical safety of  society and enables immediate action in the event of an epidemiological threat. The Center will include the BSL-3 standard epidemiological rapid response laboratory – the first in western Poland and one of only a few in the whole country. It will be characterized by one of the highest classes of biosafety, giving the possibility to work with microorganisms from various risk groups. 

Apart from its research activity, Łukasiewicz – PORT successfully applies for grants from various financing sources, both as an independent applicant and member of larger consortia or a subcontractor in implementation projects. Łukasiewicz – PORT is currently a coordinator for the Horizon Europe Widera project (HE Twinning project: SAME-NeuroID) with partners from France, Germany and the Netherlands. In addition, Łukasiewicz-Port supports its clients in developing and increasing competitiveness through technology transfer and innovation management.

Role of institution in the project

Łukasiewicz–PORT (will be involved in WP7) where can: contribute to the bench mark validation of systems and joint scientific projects; assess platform performance and provide feedback; perform additional tests, validate and monitor digital pathology systems in collaboration with labs worldwide by setting up small case studies; provide expertise in quality assessment of digital images, tissue sections and biomarker; provide expertise in visual QC assessment of data quality from classic pathological assessment vs data generated by AI; share expertise in developing research scoring systems for HEs and molecular biomarkers; validate digital pathology management systems for research and clinical trials environment.

Patrycja Gazinska

Patrycja Gazinska Ph.D. is principal investigator and Scientific Lead for the Biobank Research Group. Her group’s main research profile concerns translational research using molecular and computational pathology, with a focus on understanding how tumour microenvironment features (in HNSCC and BC) predict clinical and biological aspects of disease. For many years, Patrycja managed histopathology research projects and services for multidisciplinary teams at Kings College in London (KCL). Later, she led a Digital & Experimental Research Pathology unit at the Institute of Cancer Research (ICR) specializing in digital pathology (including image analysis) and molecular pathology (histological biomarkers development and optimisation), with specific application to TNBC. More recently she worked for AstraZeneca (AZ) in Cambridge, applying computational pathology frameworks to oncology phase III clinical trials and analysis of ultra-low HER2. Patricja’s current research program aims to understand HNSCC and its radio-resistance with application of artificial intelligence and spatial profiling. She also continue close research collaboration in BC with KCL, ICR and Royal Marsden Hospital, UK. This includes immune-oncology projects aiming to identify immunologic pathways in residual disease, to benefit high-risk patients and a novel framework of capturing immune features in lymph nodes predictive of TNBC outcome.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

March 14, 10:00-11:30 aM CET



Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.